Medical management and cardiovascular risk reduction in peripheral arterial disease

Experimental and Clinical Cardiology

Volumn 13, Issue 3, 2008, Pages 113-119

  Sethi, Ankur ^a   Arora, Rohit R ^b  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Antiplatelet agents; Cardiovascular risk; PAD

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANTICOAGULANT AGENT; APOLIPOPROTEIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; CILOSTAZOL; CLOPIDOGREL; COUMARIN; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FIBRIC ACID DERIVATIVE; FOLIC ACID; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINE; NICOTINIC ACID; PICOTAMIDE; PLACEBO; RAMIPRIL; SIMVASTATIN; THIAZIDE DIURETIC AGENT; TICLOPIDINE;

ABNORMAL LABORATORY RESULT; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLEEDING; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLAUDICATION; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; COMBINATION CHEMOTHERAPY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MEGADOSE; EMBOLISM; FOOT CARE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HOMOCYSTEINE BLOOD LEVEL; HUMAN; HYGIENE; HYPERLIPIDEMIA; HYPERTENSION; INTERMITTENT CLAUDICATION; LEUKOPENIA; LIFESTYLE MODIFICATION; LIMB ISCHEMIA; MAGNETIC RESONANCE ANGIOGRAPHY; MONOTHERAPY; MORBIDITY; MORTALITY; PREVALENCE; QUALITY OF LIFE; REVASCULARIZATION; REVIEW; RISK REDUCTION; SHOE; SMOKING; SMOKING CESSATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; TOE BRACHIAL INDEX; TREADMILL EXERCISE; VASCULAR SURGERY; WALKING;

EID: 55349128517     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007;45(Suppl S):S5-67.
2. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/ Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; ond Vascular Disease Foundation. Circulation 2006;113:e463-654.
3. Lijmer JG, Hunink MG, van den Dungen JJ, Loonstra J, Smit AJ. ROC analysis of noninvasive tests for peripheral arterial disease. Ultrasound Med Biol 1996;22:391-8.
4. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-43.
5. Skau T. Jönsson B. Prevalence of symptomatic leg ischaemia in a Swedish community - an epidemiological study. Eur J Vasc Surg 1993;7:432-7.
6. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: Prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20:384-92.
7. Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002;143:961-5.
8. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-24.
9. Clagett GP, Sobel M, Jackson MR, Lip GY, Tangelder M, Verhaeghe R. Antithrombotic therapy in peripheral arterial occlusive disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):609S-26S.
10. McDermott MM, Criqui MH, Greenland P, et al. Leg strength in peripheral arterial disease: Associations with disease severity and lower-extremity performance. J Vasc Surg 2004;39:523-30.
11. Widmer LK, Biland L, DaSilva A. Risk profile and occlusive periphery artery disease (OPAD). In: Proceedings of the 13th International Congress of Angiology. Athens, 1985:28.
12. Kannel WB, Skinner JJ Jr, Schwartz MJ, Shurtleff D. Intermittent claudication. Incidence in the Framingham Study. Circulation 1970;41:875-83.
13. Lüscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part II. Circulation 2003;108:1655-61.
14. Landray MJ, Thambyrajah J, McGlynn FJ, et al. Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis 2001;38:537-46.
15. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1999;47:1255-6.
16. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: A meta-analysis. Arch Intern Med 1999;159:337-45.
17. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007,45:645-54
18. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78. (Erraturn in 2005;366:1358).
19. Ostergren J, Sleight P, Dagenais G, et al; HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004,25:17-24.
20. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991;151:1769-76.
21. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003;26:3333-41.
22. Bønaa KH, Njølstad I, Ueland PM, et al; NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
23. Lonn E, Yusuf S, Arnold MJ, et al; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77. (Erratum in 2006;355:746).
24. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N Engl J Med 2002;347:1941-51.
25. Regensteiner JG. Exercise in treatment of claudication: Assessment and treatment of functional impairment. Vasc Med 1997;2:238-42.
26. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication. pain. A meta-analysis. JAMA 1995;274:975-80.
27. Lindemann S, Krämer B, Seizer P, Gawaz M. Platelets, inflammation and atherosclerosis. J Thromb Haemost 2007;5(Suppl 1):203-11.
28. Steinhubl SR, Moliterno DJ. The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs 2005;5:399-408.
29. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. (Erratum in 2002;324:141).
30. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985;1:415-9.
31. Goldhaber SZ, Manson JE, Stampfer MJ, et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet 1992;340:143-5.
32. Giansante C, Calabrese S, Fisicaro M, Fiotti N, Mitri E. Treatment of intermittent claudication with antiplatelet agents. J Int Med Res 1990;18:400-7.
33. Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology 1988;39:802-11.
34. Boissel JP, Peyrieux JC, Destors JM. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? Thromb Haemost 1989;29;62:681-5.
35. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE), CAPRIE Steering Committee. Lancet 1996;348:1329-39.
36. Goto S. Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 2005;6:3-11.
37. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998;27:267-74.
38. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98:678-86.
39. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Intern Med 1999;159:2041-50.
40. Regensteiner JG, Ware JE Jr, McCarthy WJ, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: Meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002;50:1939-46.
41. Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol 2001;87:28D-33D.
42. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
43. Balsano F, Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Circulation 1993;87:1563-9.
44. Döffler-Melly J, Büller HR, Koopman MM; Prins MH. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst Rev 2003:CD000536.
45. Tangelder MJ, Lawson JA, Algra A, Eikelboom BC. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. J Vasc Surg 1999;30:701-9.
46. Döffler-Melly J, Koopman MM, Prins MH, Büller HR. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2005:CD002071.
47. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis. JAMA 1999;282:2058-67. (Erratum in 2000;284:45).
48. Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007;357:217-27.